| Description |
xvi, 498 pages ; 24 cm |
| Series |
WPA series, evidence and experience in psychiatry ; v. 2 |
|
WPA series, evidence and experience in psychiatry ; v. 2
|
| Contents |
Diagnosis of Schizophrenia: A Review / C.B. Pull 1 -- 1.1 The Diagnosis of Schizophrenia: Practice and Concept / J.S. Strauss 38 -- 1.2 Should Schizophrenia as a Disease Entity Concept Survive into the Third Millennium? / T.J. Crow 40 -- 1.3 On Defining Schizophrenia / J. Parnas 43 -- 1.4 Diagnosis and Pathophysiology of Schizophrenia / P.F. Liddle 45 -- 1.5 The Significance of Intuition for the Diagnosis of Schizophrenia / A. Kraus 47 -- 1.6 Heterogeneity vs. Homogeneity in Operationally-diagnosed Schizophrenia / J.L. Waddington, P.J. Scully 50 -- 1.7 Diagnosis of Schizophrenia: Arguments for a Narrowing of the Concept / P. Berner 52 -- 1.8 Schizophrenia: A Provisional Diagnostic Convention / G. Gross, G. Huber 55 -- 1.9 Diagnosing Schizophrenia: A Personal View / A. Jablensky 58 -- 1.10 Comments on the Diagnosis of the Schizophrenic Syndrome / A. Bertelsen 60 -- 1.11 The Schizophrenic Syndrome: A Warning and a Conjecture / J.E. Cooper 62 -- 1.12 A Century of Schizophrenia is Enough / J. Kelly, R. Murray 65 -- 1.13 Diagnosis of Schizophrenia: A View from Developing Countries / N.N. Wig 68 -- 1.14 Studies on Schizophrenic Symptomatology in Peru / A. Perales 70 -- 1.15 Neuropsychological and Psychophysiological Contributions to the Diagnosis of Schizophrenia / A.F. Mirsky, C.C. Duncan 72 -- Chapter 2 Pharmacological Treatment of Schizophrenia 75 -- Pharmacological Treatment of Schizophrenia: A Review / W.W. Fleischhacker 75 -- 2.1 Pharmacotherapy of Psychotic Disorders: A Perspective on Current Developments / R.J. Baldessarini 114 -- 2.2 Pharmacotherapy of Schizophrenia: Gaps in our Knowledge / J. Kane 118 -- 2.3 Atypical Antipsychotic Drugs and Schizophrenia / H.Y. Meltzer 120 -- 2.4 Compliance Issues and the New Antipsychotics / T.R.E. Barnes 122 -- 2.5 Schizophrenia and Second-generation Antipsychotics: Mechanistic Implications and Potential for Early Intervention / J.L. Waddington, J.F. Quinn 125 -- 2.6 Dose and Duration of Antipsychotic Treatment: Key Variables, Critical Uncertainties / G.M. Goodwin 128 -- 2.7 Dosing Problems of Classical Neuroleptics and the Relevance of Novel/Atypical Antipsychotics in the Pharmacotherapy of Schizophrenic Disorders / H.-J. Moller 130 -- 2.8 Can We Use Pharmacotherapy More Logically in Schizophrenia and Other Psychoses? / P. McGorry 133 -- 2.9 Long-term Treatment in Schizophrenia: For Whom and How Long? / W. Gaebel 135 -- 2.10 Novel Antipsychotics in Schizophrenia and Related Disorders: Preliminary Findings from a First-episode Study / S. Opjordsmoen 137 -- 2.11 The Pharmacotherapy of Schizophrenia in Clinical Practice / R.S. Kalm, J.M. Van Ree 140 -- 2.12 A New Era of Hope in Treating Persons with Schizophrenia / A.F. Lehman 141 -- 2.13 New Perspectives in Antipsychotic Pharmacotherapy / J. Peuskens 143 -- 2.14 Some Aspects of the Maintenance Treatment of Schizophrenia / C.L. Cazzullo 146 -- 2.15 Highlights on the Management of Schizophrenia / A. Okasha 148 -- 2.16 Pharmacotherapy of Schizophrenia: The Case of Developing Countries / D. Moussaoui 150 -- Chapter 3 Psychotherapies for Schizophrenia 153 -- Psychotherapies for Schizophrenia: A Review / M. Birchwood, E. Spencer 153 -- 3.1 Relevant Methods, Goals, Time-dimensions and Emotional Influences in the Psychotherapy of Schizophrenia / L. Ciompi 221 -- 3.2 Family and Individual Cognitive-Behavioural Interventions / N. Tarrier 223 -- 3.3 It is no Longer Surprising that Cognitive-Behavioural Therapy Reduces Distressing Psychotic Symptoms / P.A. Garety 226 -- 3.4 Serious Questions Remain Concerning Efficacy, Effectiveness and Scope of Family Interventions in Schizophrenia / G. Szmukler 228 -- 3.5 The Interaction of Psychotherapy and Drugs in the Management of Schizophrenia: A Neglected Field / H. Katschnig 230 -- 3.6 How Effective are Psychotherapies for Schizophrenia? / M.G. Madianos 232 -- 3.7 Need for an Integrated and Need-adapted Approach in Treating Schizophrenia / V. Lehtinen 235 -- 3.8 To Integrate the Psychotherapy of Schizophrenia into the Activities of the Multidisciplinary Team, and to Base it on the Principles of Evolutionary Biology / J. Price 237 -- 3.9 Psychotherapy for Schizophrenia: An Important Addition to Medication Alone? / J. Scott 239 -- 3.10 The Effectiveness of Cognitive-Behavioural Therapy in Schizophrenia / P.M. Furlan 242 -- 3.11 Family: A System Which Cannot Be Neglected / J. Furedi, J. Abarbanel 244 -- 3.12 Psychological Interventions for Schizophrenia in Developing Countries / R. Srinivasa Murthy 246 -- Chapter 4 Prevention of Disability and Stigma Related to Schizophrenia 249 -- Prevention of Disability and Stigma Related to Schizophrenia: A Review / R. Cancro, A.T. Meyerson 249 -- 4.1 What Works for the Rehabilitation of Schizophrenia? A Brief Review of the Evidence / K.T. Mueser 285 -- 4.2 The Stigma of Mental Illness: Some Empirical Findings / J.C. Phelan 287 -- 4.3 Reducing the Stigma Associated with Schizophrenia / R. Warner 290 -- 4.4 The Influence of Stigma on Preventive Efforts in Psychotic Disorders / P. McGorry 292 -- 4.5 Disability, Stigma and Discrimination: A View from Outside the USA / H. Hafner 294 -- 4.6 The Toxic Effects of Stigma / H.M. Visotsky 297 -- 4.7 The Conceptualization of Long-term, Disabling Psychiatric Disorders / P. Ruiz 299 -- 4.8 Utility of Multiaxial Assessment in the Rehabilitative Work with Chronically Disturbed Patients / M.C. Kastrup 301 -- 4.9 "Clanning" for Recovery / U. Malm 303 -- 4.10 Stigma and Schizophrenia: The Greek Experience / M. Economou 306 -- 4.11 Disability and Stigma Prevention: The Russian Experience / V.S. Yastrebov 308 -- 4.12 Are Western Models of Psychiatric Rehabilitation Feasible and Appropriate for Developing Countries? / M.R. Phillips 310 -- 4.13 Is Schizophrenia a Chronic Illness? The Experience of Developing Countries / R. Srinivasa Murthy 313 -- 4.14 Prevention of Disability and Stigma: Experience from a Developing Country / M.R. Chaudhry 314 -- Chapter 5 Schizophrenia Spectrum Disorders 317 -- Schizophrenia Spectrum Disorders: A Review / W. Maier, P. Falkai, M. Wagner 317 -- 5.1 Extending the Schizophrenia Spectrum even Further / G. Claridge 378 -- 5.2 Schizotypy: Theoretical Considerations, Latent Structure, and the Expanded Phenotype / M.F. Lenzenweger 380 -- 5.3 Empirical Characterization of the Schizophrenia Spectrum / L.J. Ingraham 383 -- 5.4 Exploring Schizophrenia Across the Continuum / E.F. Walker 385 -- 5.5 Schizophrenia Spectrum Disorders and the Psychotic Continuum / V. Peralta 387 -- 5.6 Dimensions of Schizotypy in Symptomatic, Neurocognitive and Psychophysiological Indicators / K.H. Nuechterlein, K.L. Subotnik, R.F. Asarnow 390 -- 5.7 The Role of Syndromes and Neurophysiology in Conceptualizing the Schizophrenia Spectrum and Predisposing Influences / J. Gruzelier 392 -- 5.8 Irremediable Flaws in the Schizophrenia Spectrum Concept / C.R. Cloninger 395 -- 5.9 Do Not Dismiss the Single Major Locus Hypothesis So Quickly / P.S. Holzman, D.L. Levy, S. Matthysse 398 -- 5.10 Schizophrenia Spectrum: Where to Draw the Boundary? / G. Gross, G. Huber 401 -- 5.11 Is There a Place for the Nature-Nurture Hypothesis in the Aetiology of Schizophrenia Spectrum Disorders? / A.F. Mirsky, C.C. Duncan 404 -- 5.12 Schizophrenia Spectrum -- a "Terra Flexibilis" / A. Marneros 406 -- 5.13 Some Open Research Issues Concerning Schizophrenia Spectrum Disorders / J.D. Guelfi 408 -- 5.14 Schizophrenia Spectrum Disorders Revisited / M.A. Javed 409 -- Chapter 6 Economics of Schizophrenia 413 -- Economics of Schizophrenia: A Review / M. Knapp, J. Simon, M. Percudani, S. Almond 413 -- 6.1 Is Schizophrenia Worth the Cost? / G. Andrews 461 -- 6.2 Morality and Cost in the Management of Schizophrenia / P. Bebbington 464 -- 6.3 Caveat Emptor: Pitfalls in Measuring the Costs of Schizophrenia / R. Warner 466 -- 6.4 The Economic Consequences of Schizophrenia / S.S. Sharfstein 468 -- 6.5 The Many and the Few: Evidence-based Mental Health in a Primary-care-led Health Service / L. Gask 470 -- 6.6 The Long-term Course of Schizophrenia and its Economic Consequences / D. Wiersma 472 -- 6.7 Health Economics in Schizophrenia: Clouding or Clarifying? / T. Burns 474 -- 6.8 The Economic Burden of Schizophrenia / M. De Hert, J. Peuskens 477 -- 6.9 Lack of Comprehensive Care for Schizophrenic Patients: Is it Due to Prohibitive Costs or Insufficient Advocacy? / T. Detre 478 -- 6.10 The Role of Cost-effectiveness Analysis in Improving the Treatment of Schizophrenia / H.Y. Meltzer 481 -- 6.11 Medical Cost Outcomes of the Atypical Antipsychotics / D.A. Revicki 483 -- 6.12 The Costs of Schizophrenia -- New Treatments and New Economics / M. Sabshin 486 |
| Summary |
Be Guided by the Evidence. In this new edition of the second volume in the WPA Series, Evidence and Experience in Psychiatry, focuses on the controversial issues surrounding schizophrenia. By using systematic reviews with accompanying commentaries this volume is able to assess the 'evidence' and 'experience' to give a critical and objective account of the relevant issues, while focusing on key topics, such as diagnosis and prevention of disability and stigma. |
| Bibliography |
Includes bibliographical references and index |
| Subject |
Schizophrenia.
|
|
Schizophrenia.
|
| Author |
Sartorius, N.
|
|
Maj, Mario, 1953-
|
| LC no. |
2003535173 |
| ISBN |
0470849649 |
|
